FiercePharma

Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate ...

Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer RARITAN, N.J., ...
JD Supra

Janssen’s abiraterone acetate and prednisone combination therapy patent found invalid

On January 14, 2020, the Federal Court released a decision by Phelan J. in patent infringement actions pursuant to subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (PMNOC ...
Business Wire

New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and ...

BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV today announced additional data from the pivotal Phase 3 LATITUDE clinical trial, which showed that treatment with Zytiga ® ...
FierceBiotech

Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer

RARITAN, N.J., Oct. 11 /PRNewswire/ -- Results from a pre-specified interim analysis of a randomized, placebo-controlled Phase 3 study, COU-AA-301, demonstrate that patients treated with the ...
ascopubs.org

Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study. Background: Abiraterone acetate (AA) is an inhibitor ...